GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder

A long-term study suggests GLP-1 agonists, especially semaglutide, may lower the risk of alcohol use disorder hospitalizations, highlighting the potential for novel treatments pending further clinical trials.

Semaglutide injection pen control blood sugar levels
Study: Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. Image Credit: Artmim/Shutterstock.com

In a recent study published in JAMA Psychiatry, a team of researchers from Europe investigated whether glucagon-like peptide-1 receptor (GLP-1) agonists, which are primarily used to treat diabetes and obesity, could be used to reduce alcohol use disorder (AUD)-related hospitalizations.

They analyzed Swedish registry data and evaluated whether GLP-1 agonists, particularly liraglutide and semaglutide, could offer new avenues for mitigating the adverse impacts of AUD.

Background

Alcohol use disorder contributes significantly to the global disease burden, and although various psychosocial and pharmacological treatment options for AUD are available, they are often under-utilized. Furthermore, existing medications for AUD, such as disulfiram, naltrexone, and acamprosate, demonstrate varying efficacy, highlighting the need for alternative therapeutic options.

Recent findings suggest that GLP-1 agonists, which are widely prescribed for diabetes and obesity, might influence alcohol consumption behaviors. Preclinical research in animals and observational studies in humans have linked GLP-1 receptor pathways to reduced cravings and lower alcohol intake, potentially mediated by dopamine modulation in reward mechanisms.

Furthermore, genetic associations between GLP-1 receptors and AUD indicate a biological overlap that warrants further examination. Although Danish registry studies have reported transient benefits from GLP-1 agonist use on alcohol-related outcomes, comprehensive data on long-term impacts and broader clinical effectiveness are limited.

About the study

In the present study, the researchers utilized the national registry data from Sweden to examine whether GLP-1 agonists could positively impact the risk of AUD-related hospitalizations. A cohort of over 200,000 individuals between the ages of 16 and 64 with an AUD diagnosis between 2006 and 2023 was identified from the registries, which provided data on inpatient care, outpatient visits, and social insurance.

The primary exposure examined in the study was GLP-1 agonist use, which included semaglutide, liraglutide, and others. This was compared to non-use of GLP-2 during the follow-up periods for the same individual. A secondary comparison examined the effects of medications approved for AUD, such as disulfiram, acamprosate, and naltrexone.

The primary outcome was AUD-related hospitalizations, which were analyzed using a Cox regression model with a within-individual design. This method controlled for confounding factors by comparing the same individuals during periods of medication use versus non-use. Additionally, secondary outcomes such as hospitalizations for substance use disorders, somatic conditions or intense physical symptoms due to emotional distress, and suicide attempts were also examined.

Furthermore, the researchers used statistical models to account for variables such as psychotropic medication use, antidiabetic treatments, and temporal factors. Hazard ratios (HR) were adjusted for confounders, providing a robust estimate of associations. Additionally, the study analyzed specific GLP-1 agonists and AUD medications individually, and the results for AUD medications were aggregated for comparison.

Results

The researchers found that the use of GLP-1 agonists significantly reduced the risk of AUD-related hospitalizations compared to periods of non-use within the same individuals. Among the various medications analyzed, semaglutide showed the most substantial impact, with an adjusted HR of 0.64 for AUD-related hospitalizations and 0.68 for substance use disorder-related hospitalizations. Liraglutide was associated with similar beneficial effects, demonstrating an adjusted HR of 0.72 for AUD and 0.78 for substance use disorder-related hospitalizations.

In comparison, traditional AUD medications cumulatively provided only a modest reduction in the risk for AUD-related hospitalizations, with an adjusted HR of 0.98. However, specific AUD treatments displayed relatively better outcomes within this group.

Naltrexone demonstrated the most notable reduction in hospitalization risk, with an adjusted HR of 0.86 for both AUD- and substance use disorder-related hospitalizations. Although disulfiram and acamprosate provided more modest effects, their effectiveness was comparatively limited when evaluated against the stronger impacts of semaglutide and liraglutide.

Furthermore, examination of the secondary outcomes reported that semaglutide and liraglutide were linked to reduced risks of hospitalizations for somatic conditions, with liraglutide and semaglutide showing an adjusted HR of 0.79 and 0.78, respectively. However, these medications did not demonstrate statistically significant changes in suicide attempt risks, though the adjusted HR for semaglutide indicated promise.

Interestingly, the tested GLP-1 agonists outperformed the traditional AUD medications in reducing AUD-related hospitalization risks, highlighting their potential as a novel treatment approach. These results also aligned with emerging preclinical data that indicate GLP-1 receptor involvement in reward pathways as a potential mitigating factor for alcohol cravings and consumption.

Conclusions

Overall, the study suggested that GLP-1 agonists, particularly liraglutide and semaglutide, were promising options for reducing AUD-related hospitalizations. Their superior performance over traditional AUD medications also highlighted the potential for broader therapeutic applications, such as the treatment of somatic symptom disorder and substance use disorders. However, the researchers emphasized that randomized clinical trials were imperative to confirm these findings and establish their role in AUD treatment frameworks.

Journal reference:
Dr. Chinta Sidharthan

Written by

Dr. Chinta Sidharthan

Chinta Sidharthan is a writer based in Bangalore, India. Her academic background is in evolutionary biology and genetics, and she has extensive experience in scientific research, teaching, science writing, and herpetology. Chinta holds a Ph.D. in evolutionary biology from the Indian Institute of Science and is passionate about science education, writing, animals, wildlife, and conservation. For her doctoral research, she explored the origins and diversification of blindsnakes in India, as a part of which she did extensive fieldwork in the jungles of southern India. She has received the Canadian Governor General’s bronze medal and Bangalore University gold medal for academic excellence and published her research in high-impact journals.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sidharthan, Chinta. (2024, November 18). GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder. News-Medical. Retrieved on December 06, 2024 from https://www.news-medical.net/news/20241118/GLP-1-drugs-like-semaglutide-lower-risk-of-hospitalizations-for-alcohol-use-disorder.aspx.

  • MLA

    Sidharthan, Chinta. "GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder". News-Medical. 06 December 2024. <https://www.news-medical.net/news/20241118/GLP-1-drugs-like-semaglutide-lower-risk-of-hospitalizations-for-alcohol-use-disorder.aspx>.

  • Chicago

    Sidharthan, Chinta. "GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder". News-Medical. https://www.news-medical.net/news/20241118/GLP-1-drugs-like-semaglutide-lower-risk-of-hospitalizations-for-alcohol-use-disorder.aspx. (accessed December 06, 2024).

  • Harvard

    Sidharthan, Chinta. 2024. GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder. News-Medical, viewed 06 December 2024, https://www.news-medical.net/news/20241118/GLP-1-drugs-like-semaglutide-lower-risk-of-hospitalizations-for-alcohol-use-disorder.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Holistic lifestyle interventions outshine drugs in preventing cardiometabolic diseases